Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma

Publication date: Available online 22 November 2016 Source:Pulmonary Pharmacology & Therapeutics Author(s): Makoto Yoshida, Yasuko Kaneko, Akiko Ishimatsu, Masashi Komori, Tomoaki Iwanaga, Hiromasa Inoue The effects of tiotropium, an inhaled long-acting muscarinic antagonist, on lung function were investigated in current smokers and nonsmokers with asthma treated with inhaled corticosteroids (ICSs) and other asthma controllers: inhaled long-acting β2 agonists, leukotriene receptor antagonists, and/or theophylline. We conducted a double-blind, placebo-controlled study of an inhaled single dose of tiotropium in 9 asthmatics currently smoking and 9 asthmatics who have never smoked in a crossover manner. Lung function was measured before and 1, 3, and 24 h after inhalation of 18 μg of tiotropium or a placebo. The primary outcome was a change in forced expiratory volume in 1 s (FEV1) from the baseline, and the secondary outcomes were changes in peak expiratory flow rate (PEFR), V ˙ 50 , and V ˙ 25 . At baseline, asthmatics with and without a smoking history had a mean FEV1 of 2590 ml and 2220 ml and were taking a mean dose of ICSs of 1208 and 1000 μg/day, respectively. The increase from the baseline FEV1 was 169 ml and 105 ml higher at 3 h after tiotropium than after the placebo in current smokers and nonsmokers, respectively. PEFR, V ˙ 50 , and V ˙ 25 were also significantly increased after tiotropium as compared with the placebo i...
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research